AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
Investor's Business Daily on MSN10h
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer DrugAstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback